Stephen J. Peroutka
#113,280
Most Influential Person Now
Stephen J. Peroutka's AcademicInfluence.com Rankings
Stephen J. Peroutkamedical Degrees
Medical
#1575
World Rank
#1927
Historical Rank
Pharmacology
#139
World Rank
#175
Historical Rank
Download Badge
Medical
Why Is Stephen J. Peroutka Influential?
(Suggest an Edit or Addition)Stephen J. Peroutka's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. (1979) (1351)
- Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. (1980) (830)
- Two distinct central serotonin receptors with different physiological functions. (1981) (631)
- Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. (1980) (527)
- Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes (1987) (414)
- The effect of systemically administered recombinant human nerve growth factor in healthy human subjects (1994) (391)
- Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors (1985) (357)
- 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization (1988) (325)
- Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. (1988) (313)
- 5-Hydroxytryptamine receptor subtypes. (1990) (294)
- A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors (1992) (269)
- Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain (1977) (267)
- Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans (1997) (235)
- Differential effects of 5-hydroxytryptamine1A selective drugs on the 5-HT behavioral syndrome (1986) (232)
- 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain (1989) (219)
- Dopamine and migraine (1997) (209)
- Regulation of serotonin2 (5-HT2) receptors labeled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. (1980) (207)
- Neurotransmitter receptor binding in bovine cerebral microvessels. (1980) (203)
- Two distinct effects of 5-hydroxytryptamine on single cortical neurons (1987) (196)
- ANTIEMETICS: NEUROTRANSMITTER RECEPTOR BINDING PREDICTS THERAPEUTIC ACTIONS (1982) (194)
- Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment (1986) (184)
- The molecular evolution of G protein-coupled receptors: Focus on 5-hydroxytryptamine receptors (1994) (177)
- Characterization of the human 5-hydroxytryptamine1B receptor. (1992) (176)
- Two distinct serotonin receptors: regional variations in receptor binding in mammalian brain (1981) (176)
- Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Nco I alleles (1997) (175)
- Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. (1989) (172)
- 5-hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: A polymerase chain reaction study (1996) (162)
- 5‐Hydroxytryptamine receptor “families” (1989) (156)
- Serotonin receptor subtypes : basic and clinical aspects (1991) (144)
- Phorbol ester effects on neurotransmission: interaction with neurotransmitters and calcium in smooth muscle. (1985) (144)
- Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes (1990) (142)
- Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. (2001) (141)
- Serotonin Receptor Subtypes (1995) (134)
- [3H]Mianserin: differential labeling of serotonin and histamine receptors in rat brain. (1981) (133)
- Identification of a single amino acid residue responsible for the binding of a class of beta-adrenergic receptor antagonists to 5-hydroxytryptamine1A receptors. (1992) (130)
- 5‐Hydroxytryptamine Receptors (1993) (130)
- Neurogenic inflammation and migraine: implications for the therapeutics. (2005) (129)
- Comorbid Migraine with Aura, Anxiety, and Depression Is Associated with Dopamine D2 Receptor (DRD2) NcoI Alleles (1998) (127)
- [3H]quipazine labels 5-HT3 recognition sites in rat cortical membranes. (1988) (122)
- Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA (1990) (118)
- What Turns on a Migraine? A Systematic Review of Migraine Precipitating Factors (2014) (112)
- Further characterization of the putative 5‐HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater (1991) (108)
- Serotonin receptor binding sites affected differentially by guanine nucleotides. (1979) (108)
- Selective labeling of 5-HT1A and 5-HT1B binding sites in bovine brain (1985) (106)
- Multiple serotonin receptors and their physiological significance. (1983) (105)
- Species variations in RU 24969 interactions with non-5-HT1A binding sites. (1986) (101)
- Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. (1987) (98)
- 5-Hydroxytryptamine receptor subtypes. (1990) (98)
- 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. (1990) (97)
- The Neuropharmacology of Serotonin (1990) (96)
- Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites (1990) (95)
- Familial hemiplegic migraine, nystagmus, and cerebellar atrophy (1996) (90)
- Migraine with aura susceptibility locus on chromosome 19p13 is distinct from the familial hemiplegic migraine locus. (2001) (88)
- Nucleotide interactions with 5-HT1A binding sites directly labeled by [3H]-8-hydroxy-2-(DI-n-propylamino)tetralin ([3H]-8-OH-DPAT). (1986) (87)
- Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex (2004) (86)
- In vivo effects of sumatriptan (GR 43175) on extracellular levels of 5-HT in the guinea pig (1990) (83)
- Calcium channel antagonist binding sites labeled by 3H-nimodipine in human brain. (1983) (78)
- Serotonin-induced contraction of canine basilar artery: mediation by 5-HT1 receptors (1983) (77)
- Developments in 5-hydroxytryptamine receptor pharmacology in migraine. (1990) (70)
- Antagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers. (1988) (69)
- Serotonin Receptor “Families” in the Central Nervous System: An Overview a (1990) (67)
- Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors. (1991) (66)
- 5-HT receptors: past, present and future (1995) (65)
- Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study. (1989) (65)
- Vascular serotonin receptors. Correlation with 5-HT1 and 5-HT2 binding sites. (1984) (64)
- Dihydroergotamine nasal spray for the acute treatment of migraine (1994) (61)
- Evidence for Distinct 5‐Hydroxytryptamine2 Binding Site Subtypes in Cortical Membrane Preparations (1989) (60)
- The Pharmacology of Current Anti‐Migraine Drugs (1990) (59)
- Analgesic safety and efficacy of diclofenac sodium softgels on postoperative third molar extraction pain. (2004) (59)
- Detection of mRNAs and alternatively spliced transcripts of dopamine receptors in rat peripheral sensory and sympathetic ganglia (1998) (57)
- Canine basilar artery contractions mediated by 5-hydroxytryptamine1A receptors. (1986) (56)
- Relative Potency and Selectivity of Calcium Antagonists Used in the Treatment of Migraine (1984) (53)
- Orally administered MDMA causes a long-term depletion of serotonin in rat brain (1988) (53)
- Hallucinations and delusions following a right temporoparietooccipital infarction. (1982) (52)
- 5-HT1 receptor sites and functional correlates (1984) (52)
- 5-hydroxytryptamine receptor subtype messenger RNAs in human dorsal root ganglia: a polymerase chain reaction study (1997) (51)
- Three-dimensional steric molecular modeling of the 5-hydroxytryptamine3 receptor pharmacophore. (1989) (51)
- Identification of 5-hydroxytryptamine1 binding site subtypes in rat spinal cord (1987) (50)
- 5-Hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals. (1995) (49)
- 5-Hydroxytryptamine1A receptors are linked to a Gi-adenylate cyclase complex in rat hippocampus. (1988) (49)
- Characterization of a novel and potent 5-hydroxytryptamine1A receptor antagonist (1991) (49)
- Regional variations in alpha adrenergic receptor interactions of [3H]-dihydroergokryptine in calf brain: implications for a two-site model of alpha receptor function. (1978) (49)
- Identification of 5‐hydroxytryptamine1D binding sites in human brain membranes (1989) (48)
- Beyond Monotherapy: Rational Polytherapy in Migraine (1998) (46)
- Recreational Use of MDMA (1990) (44)
- Differential interactions of "prosexual" drugs with 5-hydroxytryptamine1A and alpha 2-adrenergic receptors. (1986) (41)
- Sumatriptan in Acute Migraine: Pharmacology and Review of World Experience (1990) (40)
- Monoamine metabolites in the cerebrospinal fluid of recreational users of 3,4-methylenedimethoxymethamphetamine (MDMA: Ecstasy (1987) (37)
- 5‐Hydroxtryptamine 1D Receptor Agonism Predicts Antimigraine Efficacy (1991) (37)
- The calcium antagonist properties of cyproheptadine (1984) (37)
- Dual Effect of the Serotonin Agonist, Sumatriptan, on Peripheral Neurogenic Inflammation (1995) (37)
- Nifedipine in the prophylaxis of classic migraine (1989) (37)
- Species variations in 5-HT3 recognition sites labeled by 3H-quipazine in the central nervous system (1988) (36)
- 5-Hydroxytryptamine receptors in vertebrates and invertebrates: Why are there so many? (1994) (35)
- Nifedipine Versus Propranolol for the Initial Prophylaxis of Migraine (1989) (35)
- Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide. (1988) (35)
- The effects of buspirone on sleep in the rat (1986) (34)
- A possible role of serotonin receptors in antidepressant drug action. (1982) (34)
- Serotonin receptor and reuptake sites: pharmacologic significance. (1990) (34)
- 5‐Hydroxytryptamine receptor subtypes and the pharmacology of migraine (1993) (34)
- Modulation of 5‐Hydroxytryptamine1A Receptor Density by Nonhydrolyzable GTP Analogues (1990) (34)
- Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine, and pimozide (1986) (31)
- Exclusion of 5‐HT2A and 5‐HT2C Receptor Genes as Candidate Genes for Migraine (1996) (31)
- Central effects of RDS-127: Sexual behavior after intracerebroventricular administration and in vitro receptor binding studies (1985) (30)
- Autoradiographic localization of 5-HT1 receptors to human and canine basilar arteries (1984) (29)
- Modulation of neuronal activity in the hippocampus by 5-hydroxytryptamine and 5-hydroxytryptamine1a selective drugs (1987) (29)
- Pharmacological differentiation of human 5-HT1B and 5-HT1D receptors. (1994) (27)
- Antagonist properties of d-LSD at 5-hydroxytryptamine2 receptors. (1990) (27)
- Differentiation of muscarinic cholinergic receptor subtypes in human cortex and pons: implications for anti-motion sickness therapy. (1988) (27)
- The Third Intracellular Loop of the 5‐Hydroxytryptamine2A Receptor Determines Effector Coupling Specificity (1995) (27)
- Serotonin receptor subtypes and neuropsychiatric diseases: focus on 5-HT1D and 5-HT3 receptor agents. (1991) (27)
- (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes. (1988) (26)
- Antidepressant interactions with 5-hydroxytryptamine3 receptor binding sites. (1989) (25)
- Neurotransmitter receptor binding studies predict antiemetic efficacy and side effects. (1986) (25)
- Artifactual High‐Affinity and Saturable Binding of [3H]5‐Hydroxytryptamine Induced by Radioligand Oxidation (1986) (24)
- Phylogenetic tree analysis of G protein-coupled 5-HT receptors: Implications for receptor nomenclature (1992) (23)
- Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors (2004) (23)
- The clinical utility of pharmacological agents that act at serotonin receptors. (1989) (23)
- 'Ecstasy': a human neurotoxin? (1989) (22)
- Glucose regulation in headache: implications for dietary management (2002) (22)
- Distribution of muscarinic cholinergic receptors in the dorsal vagal complex and other selected nuclei in the human medulla (1988) (21)
- Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex (1988) (21)
- 5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates. (1996) (21)
- Binding Potency of Paroxetine Analogues for the 5‐Hydroxytryptamine Uptake Complex * (1992) (20)
- Basic mechanisms of action of drugs used in the treatment of essential tremor. (1990) (18)
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopamine D2 receptor hypersensitivity in the mouse is transient. (1985) (17)
- [3H]3,4-methylenedioxymethamphetamine (MDMA) interactions with brain membranes and glass fiber filter paper. (1987) (17)
- Analysis of Internet Sites for Headache (2001) (17)
- An Alu sequence interrupts a human 5-hydroxytryptamine1D receptor pseudogene. (1993) (16)
- Differential radioligand binding properties of [3H]5-hydroxytryptamine and [3H]mesulergine in a clonal 5-hydroxytryptamine1C cell line (1992) (16)
- Anti‐Migraine Drug Interactions with Cloned Human 5‐Hydroxytryptamine 1 , Receptor Subtypes (1993) (16)
- Distribution of cholecystokinin receptors in the dorsal vagal complex and other selected nuclei in the human medulla (1989) (15)
- Recognition of multiple serotonin receptor binding sites. (1982) (15)
- Quantitative molecular analysis predicts 5-hydroxytryptamine3 receptor binding affinity. (1990) (15)
- [3H]8-OH-DPAT 'specifically' labels glass fiber filter paper. (1986) (14)
- Dual Effect of the Serotonin Agonist, Sumatriptan, on Peripheral Neurogenic Inflammation (1995) (14)
- Cyclic adenosine 3',5'-monophosphate metabolism in activated T-cell clones. (1989) (14)
- The value of genotyping for apolipoprotein E alleles in relation to vitamin E supplementation. (2000) (13)
- Genetic basis of migraine. (1998) (13)
- '[3H]quipazine' degradation products label 5-HT uptake sites. (1989) (13)
- 2008: The Year in Review (2009) (13)
- Analysis of 5-HT1 binding site subtypes and potential functional correlates. (1986) (13)
- Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat (1989) (12)
- Differential binding of ergot compounds to human versus rat 5-HT2 cortical receptors. (1994) (12)
- 6-substituted tricyclic partial ergoline compounds are selective and potent 5-hydroxytryptamine1A receptor agents. (1990) (12)
- Buspirone, 8-OH-DPAT and ipsapirone: effects on hippocampal cerebellar and sciatic fiber excitability (1988) (11)
- Neurochemistry and neurotoxicity of substituted amphetamines. (1990) (11)
- Sympathetic Look at Genetic Basis of Migraine (2002) (11)
- Serum Glucose Regulation and Headache (2002) (11)
- Step-wise analysis of polymorphisms in the human dopamine D2 receptor gene (1998) (10)
- Chemotherapeutic agents do not interact with neurotransmitter receptors (2004) (10)
- d-Lysergic acid diethylamide differentially affects the dual actions of 5-hydroxytryptamine on cortical neurons (1990) (10)
- Identification of 5-hydroxytryptamine1A receptor agents using a composite pharmacophore analysis and chemical database screening (1991) (10)
- Binding Characteristics of a Quaternary Amine Analog of Serotonin: 5-HTQ (1991) (10)
- Postsynaptic localization of 5-HT1D receptor binding sites in human caudate (1991) (10)
- Cortical and striatal variations in drug competition studies with putative 5-hydroxytryptamine1D binding sites (1991) (9)
- Calcium channel antagonism by pizotifen. (1985) (9)
- Calcitonin Gene-Related Peptide Targeted Immunotherapy for Migraine: Progress and Challenges in Treating Headache (2014) (9)
- Autosomal dominant transmission of the "photic sneeze reflex". (1984) (9)
- 2009: Year in Review (2010) (8)
- Identification of 5-hydroxytryptamine binding site subtypes in rat spinal cord. (1987) (8)
- 2010: Year in Review (2011) (8)
- Clinical Trials Update. 2013: Year in Review (2014) (7)
- Structural determinants of 5-HT1A versus 5-HT1D receptor binding site selectivity. (1991) (7)
- The medical utility of genomics data in neuropsychiatry: mutational genetics versus association genetics. (1997) (7)
- R(−)-2,5-Dimethoxy-4-77bromoamphetamine [77Br-R(−)DOB]: a novel radioligand which labels a 5-HT binding site subtype (1988) (7)
- Differential modulation of 5-hydroxytryptamine1D binding sites by GTP a and GTPgammaS (1990) (7)
- Re: a sympathetic view of "2003 Wolff Award: possible parasympathetic contributions to peripheral and central sensitization during migraine". (2004) (6)
- 2011: Year in Review (2012) (6)
- 5-Hydroxytryptamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (6)
- G protein coupled receptors (1994) (6)
- New vistas on 5-HT receptors and migraine (1991) (6)
- THE D2 RECEPTOR NCOI ALLELE : ABSENCE OF ALLELIC ASSOCIATION WITH MIGRAINEWITH AURA. AUTHOR'S REPLY (1998) (5)
- Neurotransmitter Receptors in Adult Tottering (tg/tg) Mice (1990) (5)
- 5-benzyloxytryptamine: a relatively selective 5-hydroxytryptamine 1D/1B agent. (1991) (5)
- An overview of 5-hydroxytryptamine receptor families (1991) (5)
- Clinical Trials Update 2014: Year in Review (2015) (4)
- Chronic fatigue disorders: an inappropriate response to arginine vasopressin? (1998) (4)
- Relative insensitivity of mice to 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity (1988) (4)
- “Specific” [3H]8-OH-DPAT binding to glass fiber filter paper: Implications for the analysis of serotonin binding site subtypes (1987) (3)
- Combination antiemetics. (1982) (3)
- Role of neurologists in the pharmaceutical industry. (1994) (3)
- Chapter 3 5-Hydroxytryptamine receptors (1997) (2)
- Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors (1992) (2)
- R(-)-2,5-Dimethoxy-4-77Bromoamphetamine(77Br-R(-)DOB): A novel radioligand which labels a 5-HT binding site subtype (2004) (2)
- Molecular variation within the dopamine receptor DRD2 gene in migraine (2000) (2)
- A Tribute to Dr. Irvine H. Page (1991) (2)
- Wolff Award presentation 1993. Anti-migraine drug interactions with cloned human 5-hydroxytryptamine1 receptor subtypes. (1993) (2)
- 5-HYDROXYTRYPTAM INE RECEPTOR SUBTYPES (1988) (2)
- The D2 receptor Nco I allele: Absence of allelic association with migraine with aura (1998) (2)
- Dual Effect of the Serotonin Agonist, Sumatriptan, on Peripheral Neurogenic Inflammation (1995) (1)
- 5-HT1D Receptor Agonist Properties of Novel 2-(5-(((Trifluoromethyl) sulfonyl)oxy)indolyl)ethylamines and Their Use as Synthetic Intermediates. (1997) (1)
- Defining demographic cohorts in clinical trial populations using large electronic health records databases. (2022) (1)
- Not All CGRP Antagonists Are Created Equal (2013) (1)
- Families Linked and Unlinked to Chromosome 19 With Familial Hemiplegic Migraine (1996) (1)
- 5-Hydroxytryptamine1A Receptors: Pharmacological and Functional Characterization (1990) (1)
- Migraine and Headache Pathophysiology (2000) (1)
- Modulation of postdecapitation convulsions in rats by α-adrenergic and 5-hydroxytryptamine1A agents (1987) (1)
- REPLY FROM DR. S. J. PEROUTKA (1990) (0)
- Printed in the U . S . A . 5-BENZYLOXYTRYPTAMINE : A RELATIVELY SELECTIVE 5-HYDROXYTRYPTAMINE AGENT ID / IB (2002) (0)
- All Headaches Are Not Created Equal (2005) (0)
- About the so-called specific binding of [3H]8-OH-DPAT to glass fiber filter (1988) (0)
- REPLY (1989) (0)
- Short report Calcium channel antagonism by pizotifen (2004) (0)
- Hypothesis Testing of the “ Neurogenic Inflammation Theory of Migraine ” : Selective Inhibition of Dural PPE (2005) (0)
- Dopamine and migraine (1998) (0)
- 21 – Genetic Disorders of the Autonomic Nervous System (2007) (0)
- Calcitonin Gene-Related Peptide Targeted Immunotherapy for Migraine: Progress and Challenges in Treating Headache (2014) (0)
- Preface (1990) (0)
- Demographic Analysis of Industry-Sponsored Alzheimer’s Disease Trial Populations in the United States (2022) (0)
- Molecular genetics and the autonomic nervous system (2013) (0)
- Reply (1996) (0)
- Twenty‐fifth Annual Meeting The American Association for the Study of Headache June 24, 25 and 26, 1983, Toronto, Ontario, Canada (1983) (0)
- THE EVOLUTION OF COGNITION TRIALS: 2003-2018 (2018) (0)
- Molecular graphics applied to 5-HT3 ligands (1991) (0)
- DOPAMINE AND MIGRAINE. AUTHOR'S REPLY (1998) (0)
- Characterization of 5-HT1 Binding Site Subtypes Labelled by [3H]-5-Hydroxytryptamine (1989) (0)
- Receptors and the Rationale for Pharmacotherapy (1989) (0)
- Clinical trials update 2015: Year in review (2016) (0)
- 2013 Daniel H. Efron Research Award (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stephen J. Peroutka?
Stephen J. Peroutka is affiliated with the following schools:
